Loading...
NPI 1386969418 · Hewlett, NY · Rheumatology Physician
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Jordan Brodsky is a rheumatology physician provider located in Hewlett, New York. This profile covers 91 Medicare and 1 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Individual |
| Organization | Jordan Brodsky |
| Address | 1157 Broadway |
| City | Hewlett |
| State | NY |
| ZIP | 11557 |
| Taxonomy | Rheumatology Physician |
| NPI Enumerated | March 31, 2010 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $2.4M |
| Medicaid | $440 |
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
91 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| J0897 | Injection, denosumab, 1 mg | 21,720 | $20 | $391K |
| J0717 | Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 53,000 | $1 | $212K |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | 7,770 | $30 | $202K |
| 99214 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the… | 1,720 | $110 | $192.9K |
| J3111 | Injection, romosozumab-aqqg, 1 mg | 20,160 | $10 | $161.3K |
| 86235 | The lab analyst performs an assay to evaluate the patient’s serum for each antibody to an extractable nuclear antigen, also called ENA. Types of ENA antibodies include anti ribonuclear protein,… | 8,640 | $20 | $155.5K |
| 86146 | The lab analyst performs the technical lab test to analyze the sample, such as serum, for the presence of beta 2 glycoprotein I antibody. Report one unit for each antibody. | 2,850 | $30 | $71.3K |
| 86147 | The lab analyst performs the technical lab test to analyze for the presence of antibodies to cardiolipin, also called antiphospholipids. Report this code once for each immunoglobulin class the… | 2,850 | $30 | $71.3K |
| 86769 | The lab analyst performs a multiple–step immunoassay to evaluate the patient’s serum for antibodies to severe acute respiratory syndrome coronavirus 2 (SARS–CoV–2), which causes coronavirus disease… | 1,560 | $40 | $64K |
| J7328 | Hyaluronan or derivative, gelsyn-3, for intra-articular injection, 0.1 mg | 44,520 | $1 | $44.5K |
Showing 1–10 of 91
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 91 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
91 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| J3111 | 10 | 20 | 19,950 | $10 | $260.1K |
| J0717 | 9 | 30 | 46,400 | $1 | $185.1K |
| J1745 | 8 | 50 | 2,980 | $30 | $124.1K |
| J0897 | 10 | 490 | 2,820 | $20 | $84.4K |
| 86235 | 3 | 40 | 650 | $20 | $33.6K |
| 86769 | 7 | 50 | 180 | $40 | $32.3K |
| 86480 | 4 | 20 | 50 | $60 | $25.3K |
| 80307 | 40 | 120 | 70 | $60 | $23.1K |
| 86147 | 3 | 20 | 280 | $20 | $19.2K |
| 99214 | 147 | 30,450 | 90 | $100 | $19K |
Showing 1–10 of 91
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
1 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 99214 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the… | 60 | $10 | $450 |
How this provider's Medicaid billing volume and revenue compare to other New York providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. New York median
1 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| 99214 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the… | 11,962 | 16,550 | 220 | $90 | $186.8K |
Other providers in the same ZIP code as Jordan Brodsky, ranked by combined Medicare and Medicaid revenue.
| Provider | State | Taxonomy | Medicare Revenue | Medicaid Revenue |
|---|---|---|---|---|
| Tri-med Home Care Services, Inc. | NY | Home Health Agency | $0 | $286M |
| Tri-med Staffing, Inc. | NY | Home Health Agency | $0 | $180.3M |
| Michael Singer | NY | Diagnostic Radiology Physician | $1.2M | $0 |
| Rana Mongroo | NY | Rheumatology Physician | $954.4K | $0 |
| Benjamin Levine | NY | Rheumatology Physician | $933.1K | $330 |
| Tobin Abraham | NY | Rheumatology Physician | $842.8K | $160 |
| Asaf Klein | NY | Rheumatology Physician | $826.7K | $13.2K |
| Sheldon Pike | NY | Urology Physician | $327.7K | $198.6K |
| Aaron Grotas | NY | Urology Physician | $393.7K | $78.5K |
| Stuart Kaplan | NY | Rheumatology Physician | $438.6K | $5.6K |
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.